文献速递眼底病与葡萄膜炎

口服乙酰唑胺治疗炎症性囊样黄斑水肿的反应

RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE.
PubMed 文献 · Retina · 2019-01-01

这项回顾性研究纳入16例(19眼)难治性炎症性黄斑水肿患者,评估口服乙酰唑胺的疗效。平均中心黄斑亚区厚度从471.8±110.6 μm显著降至358.3±50.4 μm(P<0.0001),平均视力(logMAR)从20/54(0.43±0.25)显著改善至20/37(0.27±0.16)(P=0.003)。无光学相干断层扫描特征可预测治疗反应。

要点

  • 口服乙酰唑胺可显著降低炎症性黄斑水肿的中心黄斑亚区厚度并改善视力。
  • 基线光学相干断层扫描特征中无一项可预测乙酰唑胺治疗反应。
  • 该治疗可提供解剖和视觉获益,且无皮质类固醇相关不良反应。

核心结论

  • 对于炎症性黄斑水肿患者,乙酰唑胺治疗后视力和中心黄斑亚区厚度均有显著获益。
  • 对于难治性炎症性黄斑水肿,乙酰唑胺治疗可提供解剖和视觉获益,且无皮质类固醇相关不良反应。

研究设计与样本

  • 回顾性综述,纳入2007年至2014年间接受乙酰唑胺治疗的葡萄膜炎性或人工晶状体眼性黄斑水肿患者。
  • 61例筛查患者中16例(19眼)符合全部标准。
  • 平均年龄57.9岁(范围19.7-81.1岁)。
  • 最常见诊断为特发性葡萄膜炎(n=6,31.6%)。
  • 平均葡萄膜炎病程4.4年(范围0.2-27.5年)。

主要发现

  • 平均中心黄斑亚区厚度从471.8±110.6 μm显著降至358.3±50.4 μm(P<0.0001)。
  • 平均视力(最小分辨角对数)从20/54(0.43±0.25)显著改善至20/37(0.27±0.16)(P=0.003)。
  • 治疗前光学相干断层扫描显示视网膜内液(n=19,100%)、视网膜下液(n=8,42.1%)、视网膜前膜(n=13,68.3%)和玻璃体黄斑牵引(n=1,5.2%)。
  • 无光学相干断层扫描特征可预测治疗反应。

关键数值与推荐

  • 平均中心黄斑亚区厚度从471.8±110.6 μm降至358.3±50.4 μm(P<0.0001)。
  • 平均视力(logMAR)从20/54(0.43±0.25)改善至20/37(0.27±0.16)(P=0.003)。

临床怎么用

  • 对于难治性炎症性黄斑水肿患者,使用乙酰唑胺可提供解剖和视觉获益,且无皮质类固醇相关不良反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the treatment effect of oral acetazolamide on refractory inflammatory macular edema. METHODS: A retrospective review of identified patients with uveitic or pseudophakic macular edema treated using acetazolamide between 2007 and 2014. Visual acuity and central macular subfield thickness was determined at baseline and at first follow-up. Baseline optical coherence tomography features were analyzed as predictors of acetazolamide response. RESULTS: Sixteen patients (19 eyes) of 61 screened met all criteria. Mean age was 57.9 years (19.7-81.1). The most common diagnosis was idiopathic uveitis (n = 6, 31.6%). Mean uveitis duration was 4.4 years (0.2-27.5). Average central macular subfield thickness decreased significantly (from 471.8 ± 110.6 μm to 358.3 ± 50.4 μm) (P < 0.0001). Average visual acuity (logarithm of the minimum angle of resolution) improved significantly from 20/54 (0.43 ± 0.25) to 20/37 (0.27 ± 0.16) (P = 0.003). Pretreatment optical coherence tomographies demonstrated intraretinal fluid (n = 19, 100%), subretinal fluid (n = 8, 42.1%), epiretinal membrane (n = 13, 68.3%), and vitreomacular traction (n = 1, 5.2%). No optical coherence tomography characteristic was predictive of a response to therapy. CONCLUSION: There is a significant benefit to vision and central macular subfield thickness after acetazolamide treatment in patients with inflammatory macular edema. In patients with refractory inflammatory macular edema, treatment using acetazolamide can provide anatomical and visual benefit without corticosteroid-related adverse effects.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Pepple KL, Nguyen MH, Pakzad-Vaezi K, et al. RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE. Retina. 2019. PMID: 29346240. doi:10.1097/IAE.0000000000002044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。